Genesis Team Performs 100th TAVR
Genesis Medical Center, East Rusholme Street, has reached a Quad Cities medical milestone with successful completion of the 100th Transcatheter Aortic Valve Replacement (TAVR).
The minimally-invasive heart valve procedure was performed on an 86-year-old woman from Iowa on October 27. The patient was released from the hospital the next day. TAVR procedures were performed on three additional patients on Oct. 27, bringing the total number of TAVR procedures completed at Genesis to 103.
The 100th procedure was performed by interventional cardiologists Jon Robken, M.D., and Michael Gimbel III, M.D., cardiothoracic surgeon Dale Geiss, M.D., and anesthesiologist Stephen DeLessio, M.D.
Genesis, the first and most experienced TAVR provider in the Quad Cities area, has a procedural success rate of 100 percent. The 103 Genesis TAVR patients have ranged in age from 50 to 96 years old.
TAVR is a life-saving option for patients diagnosed with severe aortic stenosis, a progressive disease that keeps the aortic valve from opening and closing properly. Without aortic valve replacement, severe aortic stenosis is life-threatening.
Studies have shown a survival rate as low as 50 percent at two years after the onset of symptoms. Current American College of Cardiology/American Heart Association guidelines recommend valve replacement for the majority of symptomatic patients with severe aortic stenosis.
Valve replacement required open-heart surgery, where the chest bone is surgically separated to access the heart. But during the minimally invasive TAVR procedure, a balloon-expandable prosthetic aortic heart valve is delivered via a catheter. The catheter can be inserted through an incision in the femoral artery in the groin or the Genesis Team Performs 100th TAVR Procedure subclavian artery near the collar bone, through an incision between the ribs or through a small incision in the front of the chest. Once the new valve is in place and expanded, it pushes the old valve out of the way and takes over the job of regulating blood flow.
Genesis began offering TAVR after U.S. Food and Drug Administration (FDA) approval of the Edwards SAPIEN valve in April 2014. At that time, the valve was approved for the treatment of patients with severe, symptomatic aortic stenosis who are deemed inoperable or elevated risk of death or complications associated with open heart surgery. This summer, the FDA approved expanded use of the SAPIEN XT and SAPIEN 3 valves to include patients determined by a heart team to be at intermediate risk for open-heart surgery.
The FDA’s intermediate risk approval of the SAPIEN XT and SAPIEN 3 valves enables the Genesis heart team to provide this less-invasive therapy to a larger severe aortic stenosis patient population. TAVR allows patients to avoid an open-heart procedure, with benefits including relief of symptoms, improved heart function and shorter recovery period.
“It’s very rewarding to see the improvement in life expectancy and quality of life the TAVR procedure brings to our patients, who otherwise would not have received care,” said Dr. Robken, who is medical director of the Genesis Structural Heart Program. “With our growing experience, we’ve been able to shorten the procedure, lower costs, reduce the patient hospital stay and still improve our outcomes. Everyone associated with the program is pleased with its success.”
The Genesis Heart Institute, in collaboration with Cardiovascular Medicine, P.C., developed a multi-disciplinary TAVR team that takes a rigorous approach to patient care. This team includes, in addition to Drs. Robken, Geiss, Gimbel and DeLessio; cardiothoracic surgeon Eva Proctor, M.D., interventional cardiologist Nicolas Shammas, M.D., and anesthesiologists Shira Black, D.O., and James Park, M.D.
A partnership between the cardiac surgeon, interventional cardiologists, and cardiac anesthesiologists establishes the core of the TAVR Heart Team, whose members are assisted by experienced nurses and staff from the Genesis Cardiac Catheterization Lab, Operating Room, inpatient and cardiac nursing units, Cardiac Rehab and other support staff.
GMC-Davenport is a Joint Commission Top Performer® in a number of areas, including the care of heart attack, heart failure and surgical patients and has twice been named one of the nation’s Top 50 Cardiovascular Hospitals by Truven Analytics. Genesis also is a two-time recipient of the Women’s Choice Award as one of America’s best hospitals for heart care. For more information about the TAVR procedure at Genesis, contact Tami Gumpert, Valve Clinic Coordinator, at (563) 421-3934.